What Is the Newest Treatment for Incontinence?

Incontinence treatment has expanded rapidly in recent years, and there is no single “newest” option but rather a wave of innovations targeting different types of the condition. The most prominent recent additions include vibegron, a medication approved in 2020 for overactive bladder; miniaturized implantable nerve stimulators placed near the ankle; platelet-rich plasma injections for stress leakage; and app-connected biofeedback devices for pelvic floor training. Which of these matters most depends on the type of incontinence you have, because stress incontinence and urgency incontinence arise from fundamentally different problems and respond to different treatments.

Why the Type of Incontinence Matters

Stress urinary incontinence, the kind triggered by coughing, sneezing, or jumping, accounts for roughly half of all incontinence in women. About a third have mixed incontinence, and around 15 percent have pure urgency incontinence, the sudden overwhelming need to go that arrives without warning.¹ Stress incontinence is primarily a structural problem: the muscles and connective tissue supporting the urethra have weakened. Urgency incontinence is a nerve-and-muscle signaling problem: the bladder contracts when it should not. Newer treatments tend to be designed for one category or the other, so understanding which type you have shapes the entire conversation about what is new and relevant for you.

Vibegron for Overactive Bladder

For urgency incontinence and overactive bladder, the biggest pharmacological shift in recent years is the arrival of beta-3 adrenergic agonists, with vibegron being the most recently approved in the United States. Older medications for overactive bladder, the antimuscarinics, work by blocking signals that cause bladder contractions, but they also cause dry mouth, constipation, and cognitive side effects that make many people stop taking them. Vibegron works through a different receptor, relaxing the bladder muscle without those same anticholinergic effects.

In the pivotal trial, people taking vibegron had about 1.8 fewer bathroom trips per day compared with 1.3 fewer on placebo, and among those with urgency incontinence, leak episodes dropped by about 2.0 per day versus 1.4 for placebo. The drug performed comparably to the older medication tolterodine but with fewer people quitting because of side effects: about 1.7 percent on vibegron discontinued due to adverse events compared with 3.3 percent on tolterodine.² A separate phase III trial in Japan confirmed these improvements, finding that the proportion of patients who achieved complete resolution of urgency incontinence was significantly greater than placebo, with drug-related side effects comparable to placebo rates.³

The cardiovascular safety profile has been a particular selling point. Older overactive bladder medications can raise blood pressure and heart rate, which is a concern for older adults who already have cardiovascular risk. Comprehensive reviews confirm that vibegron has no clinically meaningful effects on blood pressure or heart rate, and its benefits hold up across older adults and people with coexisting prostate enlargement.⁴ Real-world data also suggest that people stick with vibegron longer than they do with older therapies, which matters because a medication only works if you keep taking it.

Miniaturized Implantable Nerve Stimulators

Nerve stimulation for bladder control is not new in concept. Percutaneous tibial nerve stimulation has been used for years: you go to a clinic, a thin needle is inserted near your ankle, and electrical pulses travel up to the nerves that regulate bladder function. The problem is that this requires repeated office visits, often weekly for months, and many people eventually stop going. The newest innovation is a coin-sized device that gets implanted under the skin near the tibial nerve in a brief outpatient procedure, then delivers stimulation automatically on a programmed schedule.

Early feasibility data showed urgency incontinence episodes dropped by a median of about 71 percent after three months of treatment, with more than 20 percent of participants becoming completely dry.⁵ Longer follow-up at six months showed the response rate climbing to 82 percent, with about a third of participants achieving complete continence and no serious device-related adverse events.⁶ At two years, about 78 percent of participants still experienced at least a 50 percent reduction in urgency leak episodes, and roughly 91 percent had not needed to add medication for their overactive bladder.⁷ Those durability numbers are encouraging because many incontinence treatments lose effectiveness over time.

At the sacral nerve level, rechargeable sacral neuromodulation systems represent another step forward. Older sacral nerve stimulators used non-rechargeable batteries that required surgical replacement every few years. The newer rechargeable version is designed to last at least 15 years, sparing patients repeated replacement surgeries.⁸ This same technology has also shown strong results for fecal incontinence, cutting weekly bowel leakage episodes by about 75 to 79 percent at six months.⁹

Urethral Bulking Agents and Injectable Therapies

For stress incontinence that is not severe enough to warrant surgery or when someone prefers to avoid it, urethral bulking injections have been around for a while. What is newer is the accumulated evidence behind specific agents. Polyacrylamide hydrogel, sold as Bulkamid, has become one of the more widely studied options. It is injected around the urethra in an office setting, adding bulk that helps keep the urethra closed during physical stress.

A systematic review found that about a quarter of women needed a second injection to get adequate results, but once that was done, both leak episodes and urine volume were significantly reduced at one year, along with meaningful quality-of-life improvements.¹⁰ Three-year follow-up data showed 82 percent of patients still reporting cure or significant improvement, with that satisfaction rate holding steady over time and no significant safety concerns.¹¹ Compared with surgical slings, bulking agents are less invasive and carry fewer risks, but they also tend to be less effective for more severe leakage.

Platelet-Rich Plasma for Stress Incontinence

One of the more genuinely novel approaches for stress incontinence involves injecting platelet-rich plasma, or PRP, into the tissues around the urethra. The idea is that concentrated growth factors from your own blood can stimulate tissue repair and strengthen the weakened sphincter area. This is still relatively early-stage, but the initial data are intriguing.

A randomized trial comparing PRP injections with sham injections found that subjective cure rates were significantly higher in the PRP group (about 32 percent versus 4 percent for sham), and measurable urine loss on pad testing was also significantly reduced at six months, with no adverse events reported.¹² A proof-of-concept trial of PRP injected into the urethral sphincter found complete dryness in 20 percent of patients and moderate improvement in another 40 percent, with measurable increases in the pressure needed to cause leakage.¹³ These numbers are modest compared with surgery, but PRP injections are minimally invasive and use your own blood, so the safety profile is appealing. More and larger trials are underway.¹⁴

Stem Cell Research

Beyond PRP, stem cell transplantation for stress incontinence has been investigated for over a decade, but the work remains largely experimental. The concept involves harvesting a patient’s own cells, typically from skeletal muscle or fat, and injecting them into the urethral sphincter to regenerate the muscle tissue that has deteriorated. Early human trials using muscle-derived stem cells showed improvements in sphincter function.¹⁵ Compared with bone marrow harvesting, muscle-derived and fat-derived stem cells can be obtained more easily and in larger quantities with minimal discomfort.¹⁶ However, critical reviews have raised questions about the validity of some animal models used and about the actual mechanisms at work. While the results are called promising, this is not yet ready for routine clinical use.¹⁷

App-Connected Pelvic Floor Training Devices

Pelvic floor muscle training is the first-line recommendation for both stress and mild urgency incontinence, but the problem has always been adherence. Doing the exercises correctly and consistently without feedback is hard. A new generation of intravaginal sensors paired with smartphone apps now provides real-time biofeedback during training, turning what used to be an abstract exercise into something you can see and track.

A randomized trial of a pressure-sensing biofeedback device found that women using it achieved a cure rate of about 20 percent compared with about 9 percent in a control group doing standard pelvic floor exercises. Symptom severity improved more, pelvic floor strength was measurably greater, and adherence to the program was better tracked and higher in the device group.¹⁸ A separate pragmatic study of the Perifit device, which uses a gamified app experience, found that 85 percent of users reported objective symptom improvement after sustained use, with progressive gains over time.¹⁹ These devices are not a replacement for more advanced treatments in moderate-to-severe incontinence, but for mild cases or as a starting point, they represent a genuine upgrade over verbal instructions and printed handouts.

Vaginal Laser Therapy and Its Uncertain Evidence

Vaginal laser treatments, using either erbium:YAG or CO2 lasers, have been marketed aggressively for stress incontinence. The theory is that laser energy applied to the vaginal wall stimulates collagen remodeling and tightens the tissue supporting the urethra. Individual trials have reported short-term symptom improvement.²⁰ Some clinicians have also tried intraurethral laser delivery for patients who did not respond to the vaginal approach, with about 77 percent reporting at least some improvement.²¹

The problem is what happens when these treatments are compared against sham procedures in rigorous trials. A meta-analysis of randomized controlled trials found that energy-based therapies did not produce statistically significant improvements in incontinence scores compared with placebo at any time point measured, from one month out to six months.²² That gap between individual unblinded studies showing benefit and blinded sham-controlled studies showing little to none is a classic pattern for procedures with a strong placebo response. Long-term data remain sparse. If a clinic is offering vaginal laser treatment for incontinence, the evidence supporting it is weaker than the marketing suggests.

Slings and Surgical Devices in Transition

Mid-urethral slings remain the most effective surgical treatment for stress incontinence, but the surgical landscape has shifted in recent years. Concerns about mesh complications led several countries to restrict or ban certain types of vaginal mesh, prompting research into alternatives. A large Scottish population-based study found that mesh sling procedures actually had lower immediate complication rates than non-mesh open surgery, though about 6 percent of mesh patients were readmitted within five years for further intervention or symptoms of complications.²³

Newer adjustable single-incision mini-slings offer a less invasive alternative to traditional slings. Meta-analyses have found that their cure rates are comparable to standard mid-urethral slings, with significantly shorter operating times and lower postoperative pain, and similar complication rates.²⁴ ²⁵ For men with incontinence after prostate surgery, electronic artificial urinary sphincters are in development that could replace the current manually operated devices, though these are still likely five to ten years from clinical availability.²⁶

Experimental Frontiers

A few treatments are too early to recommend but worth knowing about because they could reshape the field. Gene therapy for overactive bladder is in early clinical trials. One approach, known as EG-427 (now EG110A), uses a modified herpes simplex virus vector to deliver genetic material directly to the sensory nerves that trigger overactive bladder contractions. The goal is a single treatment that silences inappropriate bladder signals at their source. This is still in early human testing, and it will be years before its effectiveness and safety profile are clear.

Another experimental concept tackles one of the practical headaches with Botox injections for overactive bladder. Botox works well but requires cystoscopy for injection directly into the bladder wall, and its effects wear off every six to nine months. A new nanoparticle-gel delivery system being tested in animal models aims to deliver Botox through a simple bladder instillation instead, using spiky nanoparticles that help the drug penetrate bladder tissue without an invasive injection. In rat models, this approach significantly reduced overactive bladder contractions more effectively than free Botox alone.²⁷ If it translates to humans, it could turn a procedure requiring sedation into something closer to pouring liquid into the bladder through a catheter.

Behavioral and Cognitive Approaches

For urgency incontinence specifically, there is growing evidence that the brain plays a more active role than many people realize. Cognitive behavioral therapy has shown beneficial effects on both symptom severity and quality of life across multiple studies, though results on objective clinical measures remain mixed.²⁸ A pilot study of mindfulness-based stress reduction found that urgency incontinence episodes dropped from about four per day to about one per day after treatment, with results sustained at one year in most participants.²⁹ That pilot was small, but the magnitude of improvement was comparable to what drug trials report.

These approaches work on the logic that urgency incontinence involves learned patterns of anxiety and premature bladder response that can be unlearned. They are not replacements for other treatments, but they are essentially free of side effects and can complement medications or devices. They remain underused, partly because they require trained therapists and partly because patients and physicians alike tend to think of incontinence as a purely physical problem.

Artificial Intelligence in Diagnosis

One less visible innovation is how incontinence is diagnosed and classified. Machine learning algorithms are being applied to urodynamic testing data, which is the set of pressure and flow measurements used to distinguish different types of bladder dysfunction. These systems can detect patterns like overactive bladder contractions, classify the degree of obstruction, and even predict which treatments are likely to work for a given patient. Reported accuracy for many of these tasks runs between 80 and 95 percent.³⁰ The practical promise is that AI-assisted interpretation could make urodynamic testing more accessible and consistent, especially in settings without subspecialty expertise.³¹ Getting the diagnosis right is the prerequisite for picking the right treatment, and this is an area where errors remain common.

Who Gets Access to Newer Treatments

A persistent issue cutting across all of these innovations is that access is uneven. An analysis of Medicare beneficiaries found that minority patients were significantly less likely to receive sacral neuromodulation compared with White patients, and patients in the western United States were also less likely to be treated.³² Similar disparities show up for fecal incontinence: Black patients were significantly less likely to receive counseling about sacral neuromodulation (about 15 percent versus 29 percent for White patients) and less likely to actually receive the procedure.³³ These gaps reflect broader patterns in who gets referred to specialists, who has insurance that covers advanced procedures, and whose symptoms are taken seriously in clinical encounters. The most advanced treatment in the world does not help if it never gets offered to you.